Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by alainmange
Group name PlateformePP2I
Item Type Journal Article
Title Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro
Creator Brachet et al.
Author Guillaume Brachet
Author Renaud Respaud
Author Christophe Arnoult
Author Corinne Henriquet
Author Christine Dhommée
Author Marie-Claude Viaud-Massuard
Author Nicolas Joubert
Author Martine Pugnière
Author Valérie Gouilleux-Gruart
Abstract Antibody-drug conjugates, such as brentuximab vedotin (BTXv), are an innovative category of monoclonal antibodies. BTXv is bioconjugated via the chemical reduction of cysteine residues involved in disulfide bonds. Species of BTXv containing zero, two, four, six, or eight vedotin molecules per antibody coexist in the stock solution. We investigated the influence of drug loading on the binding of the antibody to FcRn, a major determinant of antibody pharmacokinetics in humans. We developed a hydrophobic interaction chromatography (HIC) method for separating the different species present in the stock solution of BTXv, and we purified and characterized the collected species before use. We assessed the binding of these different species to FcRn in a cellular assay based on flow cytometry and surface plasmon resonance. HIC separated the different species of BTXv and allowed their collection at adequate levels of purity. Physicochemical characterization showed that species with higher levels of drug loading tended to form more aggregates. FcRn binding assays showed that the most conjugated species, particularly those with saturated loading, interacted more strongly than unconjugated BTXv with the FcRn.
Publication Molecular Pharmaceutics
Volume 13
Issue 4
Pages 1405-1412
Date Apr 04, 2016
Journal Abbr Mol. Pharm.
Language eng
DOI 10.1021/acs.molpharmaceut.6b00082
ISSN 1543-8392
Library Catalog PubMed
Extra PMID: 26900766
Tags Antibodies, Monoclonal, antibody?drug conjugate, author, Chromatography, Gel, drug-to-antibody ratio, FcRn, Flow Cytometry, Histocompatibility Antigens Class I, Humans, Hydrophobic and Hydrophilic Interactions, hydrophobic interaction chromatography, Immunoconjugates, original, pp2i, Protein Binding, Receptors, Fc, Surface Plasmon Resonance
Date Added 2019/06/04 - 17:29:34
Date Modified 2020/01/14 - 10:26:38


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés